Skip to main navigation
iTeos Therapeutics - Cancer Immunotherapies by Design iTeos Therapeutics - Cancer Immunotherapies by Design

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us
Skip to main content

sub Financials

  • SEC Filings
  • Quarterly Results
  • Annual Reports

SEC Filing

SEC Filing Details

Document Details

Form
4/A
Filing Date
Oct 21, 2020
Document Date
Jul 23, 2020
Form Description
Amendment to a previously filed 4
Filing Group
3,4,5
Company
iTeos Therapeutics
Issuer
ITEOS THERAPEUTICS, INC.
Filer
Davis Aaron I.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
© 2021 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Socials

LinkedIn Twitter

Footer Nav

Privacy policy Terms of use